← all works
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Canadian affiliationAn author listed a Canadian institution. This is the only route the usual frame has.
Machine scores (provisional)
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Opus teacher head0.117
GPT teacher head0.370
- Teacher spread
- 0.254 · how far apart the two teachers sit on this one work
- Validation status
score_only:v0-immature-baseline· verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it
Abstract
No abstract. This is not a gap in this database — OpenAlex has none either. 23.3% of the frame is in this state, and the screen finds HALF as much metaresearch here, so the absence is a measured bias rather than a missing field.
The record
- Venue
- The Lancet Oncology
- Topic
- Cutaneous Melanoma Detection and Management
- Field
- Medicine
- Canadian institutions
- Alberta Cancer Foundation
- Funders
- National Cancer InstituteBristol-Myers Squibb
- Keywords
- IpilimumabPlaceboMedicineAdjuvantOncologyMelanomaInternal medicineStage (stratigraphy)ResectionSurgeryCancerImmunotherapyCancer researchPathology
- Has abstract in OpenAlex
- no